Page 37 - Read Online

Okaz et al. Rare Dis Orphan Drugs J. 2025;4:24 https://dx.doi.org/10.20517/rdodj.2025.15 Page 9 of 11

DECLARATIONS
Authors’ contributions
Conceptualized the perspective and drafted the manuscript: Okaz E, Vinnakota K
Drafting and revising of the manuscript: Venkat P, Muñoz E, Baines I
The manuscript was reviewed and finalized with input from all authors.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers.
2017;3:17004. DOI
2. Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic
review and meta-analysis. Orphanet J Rare Dis. 2023;18:292. DOI
3. Staedtke V, Anstett K, Bedwell D, et al. Gene-targeted therapy for neurofibromatosis and schwannomatosis: the path to clinical trials.
Clin Trials. 2024;21:51-66. DOI PubMed
4. Peduto C, Zanobio M, Nigro V, Perrotta S, Piluso G, Santoro C. Neurofibromatosis type 1: pediatric aspects and review of genotype-
phenotype correlations. Cancers. 2023;15:1217. DOI PubMed PMC
+/-
5. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1 - and c-kit-dependent bone
marrow. Cell. 2008;135:437-48. DOI
6. Joseph NM, Mosher JT, Buchstaller J, et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest
stem cells. Cancer Cell. 2008;13:129-40. DOI PubMed PMC
7. Le LQ, Liu C, Shipman T, Chen Z, Suter U, Parada LF. Susceptible stages in Schwann cells for NF1-associated plexiform
neurofibroma development. Cancer Res. 2011;71:4686-95. DOI PubMed PMC
8. Kershner LJ, Choi K, Wu J, et al. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor
microenvironment. JCI Insight. 2022:7. DOI PubMed PMC
9. Bostanthirige DH, Plante C, Vatasescu JPS, et al. Proof-of-principle of NF1 Gene Therapy in plexiform neurofibroma mice models.
bioRxiv 2025;bioRxiv 2025.01.21.634081. Available from: https://www.biorxiv.org/content/10.1101/2025.01.21.634081v1.abstract
[accessed 12 August 2025].
10. Goto-Silva L, Junqueira M. Single-cell proteomics: a treasure trove in neurobiology. Biochim Biophys Acta Proteins Proteom.
2021;1869:140658. DOI PubMed
11. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-
expressing cells. Cancer Cell. 2008;13:105-16. DOI PubMed PMC
12. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest.
2013;123:340-7. DOI
13. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment.
Science. 2002;296:920-2. DOI PubMed PMC
14. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature.
2009;459:262-5. DOI